X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

WHO Body Recommends Vaccines To Be Updated For Variants

Content Team by Content Team
13th January 2022
in News
The UK begins the biggest ever immunization program

The technical body of the World Health Organization has confirmed that the COVID-19 vaccines, which the world is using currently, may have to be reworked to ensure their effectiveness against not only Omicron but future variants as well that may arise from nowhere. The technical group which is made up of independent experts, has confirmed that they would prefer a composition change in the vaccines to fight out the variants that are in line. All in all the current dosage of the range of brands of vaccinations that are being used for fighting out Coronavirus infection, according to these experts, must undergo an overhaul.

The technical body, in a statement issued from their end, has said that the vaccine composition may as well have to be updated in order to ensure that they continue to consistently provide the WHO-recommended levels of high protection against the infection as well as variants of concern that include delta, omicron, and other future variants.

The statement added that these vaccinations need to give out long-lasting responses, are strong and wide so as to eradicate the possibility of booster doses. The experts are of an opinion that the strategy based on repeat vaccination or booster, as we call them, may not be as suitable and sustainable as it looks.

That said, the statement hasn’t spilled any beans on advocacy of Omicron-specific vaccines, at least at this stage, and throws light on more research and data sharing. As per the statement, an updated vaccine specifically made to keep a check on dominant variants all at once must be the need of the hour.

As per the reports, the makers are already in the process of developing the generation next vaccines for Omicron and alike variants which are highly contagious. Albert Bourla, Chief Executive of Pfizer, has opined that a redesigned vaccination that focuses on Omicron in all likelihood will be needed, and their company may have one furnished by March. Moderna, on the other hand, is already working on a vaccine candidate, but that will not be available before two months. WHO has time and again said that the composition of vaccines will require global coordination, and it will be unfair to let the manufacturers decide alone and take the burden.

Previous Post

To Scale Up Quantum Drug Discovery, Oxford Joins Consortium

Next Post

Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In